Abstract
4/2011
vol. 113
Review paper
Emerging therapies for the treatment of wet age-related macular degeneration – VEGF Trap-Eye
- Department of Ophthalmology, Medical University of Lublin, Lublin, Poland
- Departament of Ophthalmology, F. Chopin Specialised Hospital in Rzeszów, Rzeszów, Poland
- Department of Experimental Pharmacology, Mossakowski Medical Research Centre, Polish Academy of Science, Warsaw, Poland
- Department of Ophthalmology and Eye Hospital, Friedrich-Alexander-University of Erlangen-Nurnberg, Erlangen, Niemcy
Klinika Oczna 2011, 113 (4): 376-378
Online publish date: 2011/12/04
Age-related macular degeneration (AMD) is the leading cause of blindness in the industrialized world. The most severe form of this disease is exudative AMD. It accounts for 10% of cases of AMD and is responsible for approximately 90% cases of severe vision loss due to AMD. Anti-vascular endothelial growth factor (VEGF) therapy changed the standard-of-care for this blinding disease. This article presents one promising new drug for the treatment of exudative AMD – VEGF Trap-Eye.
Keywords
wet age-related macular degeneration, vascular endothelial growth factor, VEGF Trap-Eye, choroidal neovascularization
Integrated with
